Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

ClinicalTrials.gov lists 208 trials for Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 18.

MeSH D054438 Neoplasms Neoplasm C04 C15 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 17 Not applicable Not applicable 28 Observational Observational 28 Unknown Unknown 1 Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 17 Not applicable Not applicable 28 Observational Observational 28 Unknown Unknown 1

Trials per phase (log scale)

208 of the 208 trials are tagged with Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational
  • Unknown

Top of scale: 21

1991: 2 trials (Observational 1, Phase 2 1) 1993: 1 trials (Phase 2 1) 1994: 1 trials (Phase 2 1) 1995: 3 trials (Phase 2 2, Phase 1/2 1) 1996: 5 trials (Observational 1, Phase 2 3, Phase 1 1) 1997: 3 trials (Phase 3 1, Phase 2 2) 1998: 10 trials (Not applicable 1, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 2) 1999: 10 trials (Observational 1, Not applicable 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2000: 10 trials (Not applicable 1, Phase 2 3, Phase 1/2 2, Phase 1 4) 2001: 11 trials (Phase 2 6, Phase 1/2 2, Phase 1 3) 2002: 21 trials (Not applicable 4, Phase 3 3, Phase 2 7, Phase 1/2 1, Phase 1 6) 2003: 16 trials (Observational 1, Not applicable 4, Phase 2 5, Phase 1/2 2, Phase 1 4) 2004: 12 trials (Observational 2, Not applicable 3, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2005: 14 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 7, Phase 1/2 1, Phase 1 2) 2006: 18 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 9, Phase 1/2 1, Phase 1 2) 2007: 12 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1 3) 2008: 17 trials (Observational 7, Not applicable 1, Phase 3 5, Phase 2 2, Phase 1 2) 2009: 10 trials (Unknown 1, Observational 4, Not applicable 2, Phase 3 1, Phase 1/2 1, Phase 1 1) 2010: 11 trials (Observational 3, Not applicable 4, Phase 2 3, Phase 1 1) 2011: 2 trials (Phase 1 2) 2012: 1 trials (Not applicable 1) 2014: 1 trials (Phase 2 1) 2015: 2 trials (Observational 1, Phase 2 1) 2017: 1 trials (Phase 1 1) 2018: 1 trials (Phase 2 1) 2019: 1 trials (Phase 1/2 1) 2020: 3 trials (Phase 1 3) 2021: 1 trials (Phase 2 1) 2023: 1 trials (Phase 1 1) 2024: 1 trials (Phase 1/2 1) 2025: 1 trials (Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 1
2024 1
2023 1
2021 1
2020 3
2019 1
2018 1
2017 1
2015 2

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 50 months across 161 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 43
Phase 1/2 16
Phase 2 74
Phase 2/3 1
Phase 3 17
Not applicable 28
Observational 28
Unknown 1

How many Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 7
Active, not recruiting 6
Completed 140
Terminated 35

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 18
European Organisation for Research and Treatment of Cancer - EORTC 4

Which drugs are being tested for Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 40
Busulfan 32
Melphalan 15

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 39
Peripheral blood stem cell transplantation 34
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] 27
IR Tacrolimus 25
Filgrastime (G-CSF) 23

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 179 5
1 yr TRM 93 1
Infection 37 6
Graft versus host disease (GVHD) 34 1
Hypoxia 26 10

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative? (9)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms. Journal of thrombosis and thrombolysis 2018 Yes
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 2017 Yes
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Yes
AML transformation in 56 patients with Ph- MPD in two well defined populations. European journal of haematology 2009 Yes
Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings. Bone marrow transplantation 1992 Yes

Showing 5 of 9 publications.

Start your 14-day trial Email me all 9 publications as a PDF

Prevalence (2)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Atypical chronic myeloid leukemia Annual incidence <1 / 1 000 000 Europe Not stated Exact
Atypical chronic myeloid leukemia Annual incidence <1 / 1 000 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Atypical chronic myeloid leukemia 98824 Exact Orphanet Rare Disease Ontology (ORDO)
Atypical chronic myeloid leukemia 98824 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages